JP4412586B2 - エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 - Google Patents

エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 Download PDF

Info

Publication number
JP4412586B2
JP4412586B2 JP2003560001A JP2003560001A JP4412586B2 JP 4412586 B2 JP4412586 B2 JP 4412586B2 JP 2003560001 A JP2003560001 A JP 2003560001A JP 2003560001 A JP2003560001 A JP 2003560001A JP 4412586 B2 JP4412586 B2 JP 4412586B2
Authority
JP
Japan
Prior art keywords
compounds
compound
formula
aryl
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003560001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525315A (ja
JP2005525315A5 (enExample
Inventor
サージェル アゴールニック，
光三 赤坂
フランク ファン，
ジーン−クリストフ ハーマンジェ，
リン ホーキンス，
イーミン ジャン，
チャールズ ヨハネス，
シャン−イー リー，
パメラ マクギネス，
エリン エー． マーフィー，
ショーン シラー，
メアリー バーメウレン，
ジャーイー ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2005525315A publication Critical patent/JP2005525315A/ja
Publication of JP2005525315A5 publication Critical patent/JP2005525315A5/ja
Application granted granted Critical
Publication of JP4412586B2 publication Critical patent/JP4412586B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65502—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003560001A 2002-01-08 2003-01-08 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 Expired - Fee Related JP4412586B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34671102P 2002-01-08 2002-01-08
US37301102P 2002-04-16 2002-04-16
PCT/US2003/000390 WO2003059898A2 (en) 2002-01-08 2003-01-08 Eponemycin and epoxomicin analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2005525315A JP2005525315A (ja) 2005-08-25
JP2005525315A5 JP2005525315A5 (enExample) 2006-02-23
JP4412586B2 true JP4412586B2 (ja) 2010-02-10

Family

ID=26994981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003560001A Expired - Fee Related JP4412586B2 (ja) 2002-01-08 2003-01-08 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途

Country Status (6)

Country Link
US (2) US7524883B2 (enExample)
EP (1) EP1463719A2 (enExample)
JP (1) JP4412586B2 (enExample)
AU (1) AU2003219652A1 (enExample)
TW (1) TW200412349A (enExample)
WO (1) WO2003059898A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
SG185306A1 (en) 2004-04-15 2012-11-29 Onyx Therapeutics Inc Compounds for proteasome enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP2030981B1 (en) 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
ES2408216T3 (es) * 2004-12-07 2013-06-19 Onyx Therapeutics, Inc. Composición para la inhibición del proteasoma
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
BRPI0612607A2 (pt) * 2005-07-05 2010-12-07 Tufts College inibidores de alfa proteìna de ativação de fibroblasto
ES2415756T3 (es) 2005-11-09 2013-07-26 Onyx Therapeutics, Inc. Compuestos para la inhibición de enzimas
EP1983828A2 (en) * 2006-02-16 2008-10-29 Sma Foundation Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
ES2415632T3 (es) 2006-06-19 2013-07-26 Onyx Therapeutics, Inc. Epoxicetonas peptídicas para la inhibición del proteosoma
US7642369B2 (en) * 2006-09-12 2010-01-05 University Of Kentucky Research Foundation Epoxyketone-based immunoproteasome inhibitors
US20100240581A1 (en) * 2006-11-13 2010-09-23 The Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
EP2207791B2 (en) 2007-10-04 2019-08-07 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EP3456707B1 (en) * 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
AU2009260778B2 (en) 2008-06-17 2014-08-28 Takeda Pharmaceutical Company Limited Boronate ester compounds and pharmaceutical compositions thereof
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
CA2763099A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
CN102725300B (zh) 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2794334C (en) 2010-03-31 2018-06-12 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
BR112012025264A2 (pt) 2010-04-07 2019-09-24 Onyx Therapeutics Inc inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
TWI746422B (zh) 2014-05-20 2021-11-21 美商千禧製藥公司 用於癌症治療的方法
EP3253734B1 (en) * 2015-02-02 2020-12-23 The Regents of The University of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
SMT202400233T1 (it) 2018-04-18 2024-07-09 Constellation Pharmaceuticals Inc Modulatori di enzimi modificanti il metile, composizioni e usi degli stessi
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
WO2025092827A1 (zh) * 2023-10-30 2025-05-08 上海汇伦医药股份有限公司 一种环氧类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912133A (en) 1988-03-07 1990-03-27 Bristol-Myers Company BU-3862T antitumor antibiotic
US5071957A (en) * 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US4990448A (en) * 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
JP3107326B2 (ja) 1992-04-13 2000-11-06 日本化薬株式会社 生理活性物質ｎｋ−０４０００ｐ、ｎｋ−０４０００ｑ、その製造法及びそれを有効成分として含有する除草剤
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
BR0210112A (pt) * 2001-05-30 2004-06-08 Novartis Ag Derivados do ácido 2-{[n-(2-amino-3-(heteroarila ou arila)propionil)-aminoacil]-amino}-alquilborÈnico
WO2003033506A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Aminoborane acid derivative and proteasome inhibitory drug containing the same

Also Published As

Publication number Publication date
TW200412349A (en) 2004-07-16
US20050101781A1 (en) 2005-05-12
EP1463719A2 (en) 2004-10-06
US7524883B2 (en) 2009-04-28
JP2005525315A (ja) 2005-08-25
WO2003059898A2 (en) 2003-07-24
US20090291998A1 (en) 2009-11-26
AU2003219652A1 (en) 2003-07-30
WO2003059898A3 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
JP4412586B2 (ja) エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
CA2472479C (en) Deazapurines and uses thereof
JP5497431B2 (ja) ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
ES2359564T3 (es) Derivados de benzamida útiles como inductores de diferenciación celular.
HU219238B (en) Cyclic polyamines, process for producing them and pharmaceutical compositions containing the same
EP2374454B1 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer
WO2006074293A2 (en) Bicyclic dihydropyrimidines as eg5 inhibitors
WO2000043000A1 (en) Proteasome inhibitors
KR20240033704A (ko) 지모의 사르사사포게닌 구조를 기반으로 하는 유도체, 약물 조성물 및 그의 용도
RU2450007C2 (ru) Производные камптотецина с противоопухолевой активностью
EP3699184B1 (en) Triptolide derivative and preparation method therefor and use thereof
JP5773888B2 (ja) 癌治療に用いられるメチレンジオキシベンゾ［ｉ］フェナントリジン誘導体
CN115894607B (zh) 一种抗肿瘤的苯丙氨酸缬氨酰衍生物及其制备方法
JP4443228B2 (ja) ルミナシン類似物およびそれら用途
EP4159736A1 (en) Novel tricyclic aromatic heterocyclic compound and preparation method therefor, pharmaceutical composition and use thereof
CN118791500B (zh) 7-氧杂双环[2.2.1]庚烷-2,3-二羧酸类衍生物及其制备方法和应用
KR101532850B1 (ko) 항암 활성을 갖는 벤즈아미드 유도체 및 이의 제조 방법 및 용도
CN116813620A (zh) 一种基于hsp90蛋白靶向降解gpx4的嵌合体及制备方法和应用
US10434085B2 (en) Non-aromatic difluoro analogues of resorcylic acid lactones

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091019

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20091023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091112

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121127

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees